One To Watch

Quince Therapeutics

Company Overview

A clinical-stage biopharmaceutical company pivoting from its red blood cell drug-delivery platform toward an inhaled rapamycin pulmonary pipeline following the 2026 acquisition of Orphai Therapeutics and a $187 million financing round. Headquartered in South San Francisco and trading on Nasdaq under the ticker QNCX, Quince Therapeutics has historically focused on rare neurological diseases through its proprietary autologous intracellular drug-encapsulation platform. The May 2026 strategic reset significantly broadens Quince's scope into pulmonary disease with the addition of LAM-001, an inhaled rapamycin candidate. The company retains its eDSP encapsulation technology as a platform asset while the new pulmonary programs take strategic center stage.

Headquarters and Global Presence

Quince Therapeutics is headquartered in South San Francisco, California, a hub of the Bay Area life sciences ecosystem. The company gained an international operational footprint through its earlier acquisition of EryDel SpA, an Italian biotech that originated the eDSP red blood cell encapsulation technology underlying EryDex.

Founding and History

Quince Therapeutics has undergone several strategic transformations since its founding, most visibly marked by its 2024 acquisition of EryDel SpA, a privately held Italian biotech, in a stock-for-stock deal with potential milestone payments. The EryDel acquisition brought in the EryDex asset and its pivotal Phase III NEAT trial program in ataxia-telangiectasia. In June 2024, Quince's board unanimously rejected an unsolicited takeover proposal from Echo Lake Capital at $1.60 per share. The most consequential pivot came in May 2026 with the acquisition of Orphai Therapeutics and an accompanying $187 million private placement that reoriented the company toward pulmonary disease.

Therapy Areas and Focus

Quince's historical focus on ataxia-telangiectasia (A-T) addressed a severe, progressive rare pediatric disease with no approved disease-modifying therapies and high unmet medical need. The strategic pivot to pulmonary disease widens the company's addressable market substantially, targeting conditions where mTOR pathway dysregulation drives disease progression. Inhaled rapamycin delivery via LAM-001 is designed to achieve local therapeutic concentrations in the lung while minimizing the systemic immunosuppressive side effects associated with oral mTOR inhibitors. The combined pipeline spans rare neurological and pulmonary orphan indications, preserving the company's rare-disease identity.

Technology Platforms and Modalities

Quince's eDSP platform encapsulates small molecules within a patient's own red blood cells, converting circulating erythrocytes into sustained-release depots. Applied to dexamethasone sodium phosphate, the approach produces EryDex — designed to deliver a controlled, prolonged corticosteroid effect without the peak-and-trough toxicity of conventional dosing. Through the Orphai acquisition, Quince also gained an inhaled rapamycin formulation technology underlying LAM-001, enabling topical mTOR inhibition directly in the pulmonary compartment. These two platforms represent distinct modalities — autologous cell-based encapsulation and targeted inhaled delivery — giving the company mechanistic breadth across its rare disease focus areas.

Key Pipeline and Programs

EryDex is Quince's lead legacy asset: an autologous red blood cell-encapsulated formulation of dexamethasone sodium phosphate developed for ataxia-telangiectasia. The program completed the pivotal Phase III NEAT trial, a multicenter, randomized, double-blind, placebo-controlled international study assessing neurological function via change from baseline on the RmICARS scale at six months. Topline results did not meet the primary endpoint, and full data were subsequently published in The Lancet Neurology in August 2024. Separately, Phase III ATTeST trial data were also published, providing additional safety and efficacy characterization of EryDex across the A-T population.

LAM-001 is Quince's newly acquired inhaled rapamycin candidate, brought in through the May 2026 Orphai Therapeutics acquisition. The asset is designed to deliver the mTOR inhibitor rapamycin directly to pulmonary tissue, targeting diseases driven by mTOR pathway hyperactivation in the lung. LAM-001 anchors Quince's new pulmonary pipeline strategy, with full development timelines and clinical staging expected to firm up as integration with Orphai's team and data progresses. The specific lead indication has not yet been publicly detailed, though pulmonary conditions with established mTOR biology — such as lymphangioleiomyomatosis — represent the logical target space.

Recent Developments

On May 18, 2026, Quince acquired Orphai Therapeutics and simultaneously announced a private placement of up to $187 million — comprising $115 million upfront through Series C non-voting convertible preferred stock, plus up to approximately $72 million contingent on warrant exercise. The financing syndicate was led by Balyasny Asset Management and included Foresite Capital, Perceptive Advisors, Logos Capital, Janus Henderson Investors, and Cormorant Asset Management, signaling broad institutional endorsement of the strategic pivot. In August 2024, Phase III EryDex data were published in The Lancet Neurology following the NEAT trial's failure to meet its primary endpoint. Former Orphai CEO Brigette Roberts, M.D., joined Quince's board and executive team as part of the acquisition.

Key Personnel

Dirk Thye, M.D., serves as both Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, a dual role reflecting the company's lean clinical-stage structure and his background as a physician-executive with experience in rare and infectious disease drug development. Brigette Roberts, M.D., the former Chief Executive Officer of Orphai Therapeutics, joined Quince's board and executive leadership following the May 2026 acquisition, bringing direct expertise in pulmonary rare diseases and the LAM-001 program she helped originate.

Strategic Partnerships

The $187 million private placement anchoring the Orphai acquisition drew participation from a consortium of institutional investors including Balyasny Asset Management, Foresite Capital, Perceptive Advisors, Logos Capital, Janus Henderson Investors, and Cormorant Asset Management. The EryDex program was originally developed by EryDel SpA in Italy, which Quince acquired in mid-2024 in a stock-for-stock deal with downstream milestone payments, bringing full ownership of the eDSP platform in-house.

FAQ Section

The pivot followed the Phase III NEAT trial of EryDex failing to meet its primary endpoint in A-T, removing the near-term regulatory path for the lead asset. Rather than wind down, Quince used the May 2026 acquisition of Orphai Therapeutics and a $187 million financing to reposition around inhaled rapamycin, a mechanistically distinct approach in pulmonary disease with significant unmet need. The move preserved the company's rare-disease identity while opening a substantially larger addressable pipeline.

Hyperactivation of the mTOR (mechanistic target of rapamycin) pathway drives abnormal cell proliferation and survival in several pulmonary conditions, most notably lymphangioleiomyomatosis, where mTOR inhibition with oral rapamycin is already a validated therapeutic strategy. The challenge with systemic rapamycin is its broad immunosuppressive and metabolic side-effect burden at the doses needed for sustained benefit. Delivering rapamycin directly to the lung via an inhaled formulation like LAM-001 is intended to achieve locally effective concentrations while sharply reducing systemic exposure.

The eDSP approach loads dexamethasone sodium phosphate into a patient's own red blood cells, creating an autologous sustained-release system that circulates in the bloodstream. Because the drug is released gradually from erythrocytes over time rather than absorbed in a conventional bolus, the platform is designed to flatten the pharmacokinetic peaks associated with standard corticosteroid dosing and reduce cumulative toxicity. In A-T, the rationale was that steady corticosteroid exposure could modify neurological progression — a hypothesis that did not achieve statistical significance in the pivotal NEAT trial.

LAM-001 is an inhaled rapamycin candidate acquired through the May 2026 purchase of Orphai Therapeutics and now anchors Quince's pulmonary pipeline strategy. Full clinical staging and trial design details are being integrated following the acquisition closing. The asset's development roadmap and lead indication are expected to be defined as the Orphai scientific team — led by founder Brigette Roberts, M.D., who joined Quince's executive team — transitions into Quince's R&D structure.

Quince's pipeline now spans two distinct areas: rare neurological disease through the legacy EryDex and eDSP platform, and pulmonary rare disease through the newly acquired LAM-001 inhaled rapamycin program. The company retains the eDSP technology as a potential platform for future applications even following the NEAT trial setback. The strategic emphasis has clearly shifted to pulmonary disease, where the $187 million financing and leadership additions are concentrating resources and development activity.

Quince is a clinical-stage company at a transitional inflection point: its most advanced legacy program, EryDex, completed Phase III with a negative primary endpoint, while its new lead asset LAM-001 is at an earlier stage of clinical definition following the Orphai acquisition in May 2026. The $187 million financing provides a significant runway to advance LAM-001 through clinical proof-of-concept. Near-term milestones include disclosure of LAM-001's lead indication, clinical trial design, and an anticipated IND or Phase I entry timeline.

The investment case hinges on execution of the pulmonary pivot and early LAM-001 data generation. Key watchpoints include:

LAM-001 IND filing and Phase I initiation timeline, which will validate the credibility of the pulmonary rapamycin strategy.
Pharmacokinetic and safety data from inhaled rapamycin studies demonstrating the local-versus-systemic exposure advantage over oral dosing.
Capital deployment efficiency from the $187 million PIPE, and whether warrant exercises materialize to deliver the full raise.
Future utility of the eDSP platform — whether Quince pursues new indications or partnership opportunities for EryDex despite the A-T setback.
Competitive landscape in pulmonary mTOR inhibition, particularly if other inhaled or reformulated rapamycin programs advance in parallel.

Want to Update your Company's Profile?